A Study to Evaluate the Efficacy, Immunogenicity and Safety of an EV71 Vaccine in Healthy Infants and Children
A Phase III, Multiple-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of an Adjuvanted, Inactivated Enterovirus 71 (EV71) Vaccine in Healthy Infants and Children
Sponsor: Enimmune Corporation
A PHASE3 clinical study on Enterovirus Infections, this trial is ongoing. The trial is conducted by Enimmune Corporation and has accumulated 7 data snapshots since 2018. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
Status: Enrolling By Invitation → Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation PHASE3
-
Sep 2023 — Jul 2024 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2022 — Sep 2023 [monthly]
Enrolling By Invitation PHASE3
▶ Show 2 earlier versions
-
Dec 2021 — Jan 2022 [monthly]
Enrolling By Invitation PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Enrolling By Invitation PHASE3
First recorded
Jun 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Enimmune Corporation
For direct contact, visit the study record on ClinicalTrials.gov .